Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regional Gastrointestinal Absorption of Sotyktu (BMS-986165) in Healthy Males
NCT03873415Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2019
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of deucravacitinib in psoriasis (8 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration at 5 days, Time of maximum observed plasma concentration at 5 days and 3 more. Started Jan 2019; status: completed.
02
Drugs
deucravacitinib
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT03873415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03873415.